Issue 44, 2022
From the journal:

RSC Advances

Correction: Scalable synthesis and structural characterization of reversible KLK6 inhibitors

Andreas Baumann,a   Daniel Isak,a   Jasmin Lohbeck,a   Pravin Kumar Ankush Jagtap,b   Janosch Hennigbc  and  Aubry K. Miller*ad  

* Corresponding authors

a Cancer Drug Development Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany
E-mail: aubry.miller@dkfz.de

b Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany

c Chair of Biochemistry IV, Biophysical Chemistry, University of Bayreuth, 95447 Bayreuth, Germany

d German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, Heidelberg, Germany

Abstract

Correction for ‘Scalable synthesis and structural characterization of reversible KLK6 inhibitors’ by Andreas Baumann et al., RSC Adv., 2022, 12, 26989–26993, https://doi.org/10.1039/D2RA04670A.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D2RA90102A
Article type
Correction
Submitted
30 Sep 2022
Accepted
30 Sep 2022
First published
10 Oct 2022
This article is Open Access
Creative Commons BY license

RSC Adv., 2022,12, 28677-28677

Permissions

Request permissions

Correction: Scalable synthesis and structural characterization of reversible KLK6 inhibitors

A. Baumann, D. Isak, J. Lohbeck, P. K. A. Jagtap, J. Hennig and A. K. Miller, RSC Adv., 2022, 12, 28677 DOI: 10.1039/D2RA90102A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements